Killer Cells, Lymphokine-Activated
-
Subject Areas on Research
- Adoptive immunotherapy for malignant glioma.
- Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells.
- Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
- Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma.
- Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma.
- Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.
- Immunotherapy of malignant brain tumors.
- In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation.
- Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity.
- Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells.
- Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
- Lymphokine-activated killer cell activity after cryopreservation.
- Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
- NK and LAK susceptibility varies inversely with target cell MHC class I antigen expression in a rat epithelial tumour system.
- Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
- Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
- Prospects for cellular immunotherapy for metastatic melanoma.
- Relationship between sensitivity to natural killer cells and MHC class-I antigen expression in colon carcinoma cell lines.
- Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
- Retinoic acid modulation of alpha(1-->2) fucosyltransferase activity and sensitivity of tumor cells to LAK-mediated cytotoxicity.
- Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
- The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals.
- The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees.
- Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
-
Keywords of People
- Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology